A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors

Haemophilia

Volumn 4, Issue 6, 1998, Pages 790-798

  Lusher, J M ^a   Roberts, H R ^b   Davignon, G ^b   Joist, J H ^b   Smith, H ^b   Shapiro, A ^b   Laurian, Y ^b   Kasper, C K ^b   Mannucci, P M ^b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b NONE

Author keywords

Acute haemarthroses; FIX inhibitors; FVIII inhibitors; Haemophilia; Intramuscular haemorrhage; Recombinant factor VIIa

Indexed keywords

BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 9;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUCOSA; MULTICENTER STUDY; MUSCLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBODIES; DOUBLE-BLIND METHOD; FACTOR VIIA; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; JOINTS; MUSCLE, SKELETAL; RECOMBINANT PROTEINS; SKIN; TREATMENT OUTCOME;

EID: 0031743928     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.00209.x     Document Type: Article

References (34)

1. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
2. Hoyer LW. The incidence of factor VIII inhibitors in patients with severe haemophilia A. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC II, eds. Inhibitors to Coagulation Factors, New York, NY: Plenum Press, 1995, pp. 35-45.
3. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, and the Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with haemophilia A. N EnglJ Med 1993; 328: 453-9.
4. Bray GL, Gomperts ED, Courter S, et al. Recombinate Study Group. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with haemophilia A. Blood 1994; 83: 2428-35.
5. Addiego J, Kasper C, Abildgaard CF, et al. Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII. Lancet 1993; 342: 462-4.
6. Lusher JM. Thrombogenicity associated with Factor IX complex concentrates. Semin Hematol 1991; 28: 3-5.
7. Chavin SI, Siegel DM, Rocco TA Jr, Olson JP. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with Factor VIII deficiency and a Factor VIII inhibitor. Am J Med 1988; 85: 245-9.
8. Kernoff PBA. Porcine factor VIII: preparation and use in treatment of inhibitor patients. Progr Clin Biol Res 1984; 150: 207-24.
9. Gringeri A, Santagostino E, Tradati F, Giangrande PLF, Mannucci PM. Adverse effects of treatment with porcine FVIII. Thromb Haemostas 1991; 65: 245-7.
10. Pedersen AH, Nordfang O, Norris F, et al. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem 1990; 265: 16786-93.
11. Hoffman M, Monroe DM, Oliver JA, Roberts HR. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 1995; 86: 1794-801.
12. Macik GB, Hohneker J, Roberts HR, Griffin AM. Use of recombinant activated factor VII for treatment of a retropharyngeal haemorrhage in a haemophilic patient with high titer inhibitor. Am J Hematol 1989; 32: 232-4.
13. Hoffman M, Monroe DM, Roberts HR. Cellular actions in haemostasis. Haemostasis 1996; 26 (Suppl. 1): 12-6.
14. Hedner U, Glazer S, Pingel K, et al. Successful use of recombinant factor Vila in a patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193 (letter).
15. Hedner U, Glazer S. Management of haemophilia patients with inhibitors. Hematology/Oncology Clinics N America 1992; 6: 1035-46.
16. Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev 1993; 7: 78-83.
17. Schmidt ML, Gamerman S, Smith HE, Scott JP, DiMichele DM. Recombinant activated factor VII (rFVIIa) therapy for intracranial haemorrhage in haemophilia A patients with inhibitors. Am J Hematol 1994; 47: 36-40.
18. O'Marcaigh AS, Schmaltz BJ, Shaughnessy WJ, Gilchrist GS. Successful haemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe haemophilia A and a potent inhibitor. Mayo Clin Proc 1994; 69: 641-4.
19. Schmidt ML, Smith HE, Gamerman S, DiMichele D, Glazer S, Scott JP. Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor IX deficient patient with an inhibitor. Br JHematol 1991; 78: 460-2.
20. Ng SC. Activated recombinant factor VII in the treatment of retroperitoneal haemorrhage in a patient with factor VIII inhibitor. Ann Acad Med Singapore 1994; 23: 901-2.
21. Lusher JM. and Novo Seven Compassionate Use Investigators: Recombinant factor VIIa (Novo Seven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996; 26 (Suppl. 1): 124-30.
22. Lindley CM, Sawyer WT, Macik G, et al. Pharmaco-kinetics and pharmacodynamics of recombinant factor Vila. Clin Pharmacol Thepeutics 1994; 55: 638-48.
23. Lusher JM, Kessler CM, Laurain Y, Pierce G. Viral contamination of blood products. Lancet 1994; 344: 405-6.
24. Lusher JM, Shapiro SS, Palascak J, Rao AV, Levine PH, Blatt PM. Prothrombin concentrates in haemophiliacs with inhibitors: a multicenter therapeutic trial. N Engl J Med 1980; 303: 421-5.
25. Lusher JM, Blatt PM, Penner JA, et al. Autoplex versus Proplex: a controlled double-blind study of effectiveness in acute hemarthrosis in haemophiliacs with inhibitors to factor VIII. Blood 1983; 62: 1135-8.
26. Sjamsoedin LJM, Heijnen L, Mauser-Bunshoten EP, et al. The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to factor VIII. N EnglJ Med 1981; 305: 717-21.
27. Brettler DB, Forsberg AD, Levine PH, et al. The use of porcine Factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitors to Factor VIII. A multicenter US experience. Arch Intern Med 1989; 149: 1381-5.
28. Rice KM, Savidge GF. Novo Seven (recombinant factor VIIa) in central nervous system bleeds. Haemostasis 1996; 26 (Suppl. 1): 131-4.
29. Ingerslev J, Freidman D, Gastineau D, et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26 (Suppl. 1): 118-23.
30. Key NS, and the US rFVIIa Home Therapy Study Group. Efficacy of recombinant factor Vila (rFVIIa) when administered in the home to control joint, muscle and mucocutaneous bleeds in haemophiliacs with inhibitors. Thromb Haemost 1997; (ISTH Congress Suppl.) 51: (abstract no. PS-206).
31. Centers for Disease Control and Prevention. Hepatitis A among persons with haemophilia who received clotting factor concentrate - United States, September - December, 1995. Morbidity and Mortality Weekly Report 1996; 45: 29-32.
32. Gruppo R, Bray GL, Schroth P, Perry M, Gomperts E, for the Recombinate™ Study Group: Safety and immunogenicity of recombinant Factor VIII (Recombinate™) in previously untreated patients (PUPs) - a 6.5 year update. Thromb Haemost 1997; (ISTH Congress Suppl.) 162: (abstract no. PD-663).
33. Lusher JM, Arkin S, Abildgaard CF, Hurst D, and the Kogenate PUP Study Group: Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with haemophilia A. update of safety, efficacy and inhibitor development after seven study years. Thromb Haemost 1997; (ISTH Congress Suppl.) 162: (abstract no. PS-206).
34. Schwartz RS, Abildgaard CF, Aledort LM, et al. The Recombinant Factor VIII Study Group. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A. N Engl J Med 1990; 322: 1800-5.